Patent Review

*Author for correspondence: Tel.: +91 986 903 6606;

Shahid Medical Centre, 8-Jayanti, 353/21, RB Mehta Road, Ghatkopar (E), Mumbai 400077, India

Published Online:18 Aug 2017https://doi.org/10.4155/ppa-2017-0019

Abstract

Inhalational route for drug delivery and desired effects has been known since centuries. This lung-targeted therapy has benefited asthmatics and those with chronic respiratory problems. The technique has evolved greatly from crude pots and pipes to modern sophisticated drug-dispensing devices. This mode is effective, rapid and safe. Its outcome, however, is majorly determined by drug formulation, device structure and patient's coordinating skill. In spite of great advances in this field, more efforts are required to meet the unmet needs. This noninvasive mode is being increasingly studied for transfer of drugs for systemic action with promising results. The present article is an attempt to capture the recent development and progress in this field and review relevant newer patents.

Keywords:

Papers of special note have been highlighted as: •• of considerable interest

References

1 Sanders M. Pulmonary drug delivery: an historical overview. In: Controlled Pulmonary Drug Delivery. Smyth HDC, Hickey AJ (Eds). Springer, NY, USA, 51–73 (2011).
Google Scholar
2 Verma RK, Ibrahim M, Gracia-Contreras L. Lung anatomy and physiology and their implications for pulmonary drug delivery. In: Pulmonary Drug Delivery: Advances and Challenges. Nokhodchi A, Martin GP (Eds). John Wiley and Sons, Inc., West Sussex, UK, 1 (2015).
Google Scholar
3 Ibrahim M, Verma RK, Gracia-Contreras L. Inhalation drug delivery devices: technology update. Med. Devices (Auckl.) 8, 131–139 (2015). •• A concise, comprehensive review about the various pulmonary drug delivery devices.
Medline CASGoogle Scholar
4 Liang Z, Ni R, Zhou J, Mao S. Recent advances in controlled pulmonary drug delivery. Drug Discov. Today 20(3), 380–389 (2015). •• A review of the sustained release preparations for pulmonary use.
Medline CASGoogle Scholar
5 Carvalho TC, Peters JI, Williams RO 3rd. Influence of particle size on regional lung deposition – what evidence is there? Int. J. Pharm. 406(1–2), 1–10 (2011).
Medline CASGoogle Scholar
6 Darquenne C. Aerosol deposition in the human lung in reduced gravity. J. Aerosol Pulm. Drug Deliv. 27(3), 170–177 (2014).
MedlineGoogle Scholar
7 Smith KJ, Chan H-K, Brown KF. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J. Aerosol Med. 11(4), 231–245 (2009).
Google Scholar
8 Sheth P, Stein SW, Myrdal PB. Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers. AAPS PharmSciTech. 16(1), 192–201 (2015).
Medline CASGoogle Scholar
9 Nickel S, Clerkin CG, Selo MA, Ehrhardt C. Transport mechanisms at the pulmonary mucosa: implications for drug delivery. Expert Opin. Drug Deliv. 13(5), 667–690 (2016).
Medline CASGoogle Scholar
10 Singh A, Malviya R, Sharma PK. Pulmonary drug delivery system: a novel approach for drug delivery. Curr. Drug Ther. 6, 137–151 (2011).
CASGoogle Scholar
11 Denyer J, Dyche T. The adaptive aerosol delivery (AAD) technology: past, present, and future. J. Aerosol Med. Pulm. Drug Deliv. 23(S1), S1–S10 (2010). •• A comprehensive review on the newer techniques in drug delivery via lungs.
Medline CASGoogle Scholar
12 Activaero Gmbh: US20100092397 (2010).
Google Scholar
13 Hardaker LE, Hatley RH. In vitro characterization of the I-Neb adaptive aerosol delivery (AAD) system. J. Aerosol Med. Pulm. Drug Deliv. 23(Suppl. 1), S11–S20 (2010).
Medline CASGoogle Scholar
14 Dhand R. Intelligent nebulizers in the age of the internet: the I-Neb adaptive aerosol delivery (AAD) system. J. Aerosol Med. Pulm. Drug Deliv. 23(Suppl. 1), iii–v (2010).
MedlineGoogle Scholar
15 Carvalho TC, McConville JT. The function and performance of aqueous aerosol devices for inhalation therapy. J. Pharm. Pharmacol. 68(5), 556–578 (2016).
Medline CASGoogle Scholar
16 Zhou QT, Tang P, Leung SS, Chang JG, Chan HK. Emerging inhalation aerosol devices and strategies: where are we headed? Adv. Drug Deliv. Rev. 75, 3–17 (2014).
Medline CASGoogle Scholar
17 Aerogen, Inc.: US20090134235 (2009).
Google Scholar
18 de Boer AH, Wissink J, Hagedoorn P et al. In vitro performance testing of the novel MedSpray^® wet aerosol inhaler based on the principle of Rayleigh break-up. Pharm. Res. 25(5), 1186–1192 (2008).
MedlineGoogle Scholar
19 Boonen P. HDA – a new pulmonary drug delivery platform can provide for more efficient and safer delivery. On Drug Delivery 1, 8–10 (2011).
Google Scholar
20 Chan JGY, Wong J, Zhou QT, Leung SSY, Chan H-K. Advances in device and formulation technologies for pulmonary drug delivery. AAPS Pharm. Sci. Tech. 15(4), 882–897 (2014).
Medline CASGoogle Scholar
21 Nikander K, Nicholls C, Denver J, Pritchard J. The evolution of spacers and valved holding chambers. J. Aerosol Med. Pulm. Drug Deliv. 27(Suppl. 1), S4–S23 (2014).
MedlineGoogle Scholar
22 Chan AH, Harrison J, Black PN, Mitchell EA, Foster JM. Using electronic monitoring devices to measure inhaler adherence: a practical guide for clinicians. J. Allergy Clin. Immunol. Pract. 3(3), 335–349 (2015). •• An excellent review about the various compliance monitoring devices available and how to use and ready them.
MedlineGoogle Scholar
23 Kaur I, Aggarwal B, Gogtay J. Integration of dose counters in pressurized metered-dose inhalers for patients with asthma and chronic obstructive pulmonary disease: a review of evidence. Expert Opin. Drug Deliv. 12(8), 1301–1310 (2015).
Medline CASGoogle Scholar
24 Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech. 15(2), 434–455 (2014). •• An excellent review on pressurized metered-dose inhaler and its formulations.
Medline CASGoogle Scholar
25 de Boer A, Hagedoorn P, Hoppentocht M, Buttini F, Grasmeijer F, Frijlink HW. Dry powder inhalation: past, present and future. Exp. Opin. Drug Deliv. 14(4), 499–512 (2017).
Medline CASGoogle Scholar
26 Alexza Pharmaceuticals: US7581540 (2009).
Google Scholar
27 3M Innovative Properties Company: EP1996173 (2008).
Google Scholar
28 Lavorini F, Fontana GA, Usmani OS. New inhaler devices – the good, the bad and the ugly. Respiration 88, 3–15 (2014).
MedlineGoogle Scholar
29 Perriello EA, Sobieraj DM. The Respimat soft mist inhaler, a novel inhaled drug delivery device. Conn. Med. 80(6), 359–364 (2016).
MedlineGoogle Scholar
30 Cipolla D, Blanchard J, Gonda I. Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics 8(1), 6 (2016).
Google Scholar
31 Ventaira Pharmaceuticals, Inc.: US20080308095 (2008).
Google Scholar
32 Tanaka Kikinzoku Kogyo KK: EP2644282 (2013).
Google Scholar
33 Novartis Ag: US8616195 (2013).
Google Scholar
34 Island Breeze systems Co., Inc.: WO2016187156 (2016).
Google Scholar
35 Ehtezazi T. Recent patents in pressurised metered dose inhalers. Recent Pat. Drug Deliv. Formul. 6(1), 31–44 (2012).
Medline CASGoogle Scholar
36 3M Innovative Properties Company: US20170021117 (2017).
Google Scholar
37 Map Pharmaceuticals, Inc.: US20170007786 (2017).
Google Scholar
38 Koninklijke Philips Electronics NV: US8960189 (2015).
Google Scholar
39 Virginia Commonwealth University: WO2013169473 (2013).
Google Scholar
40 Respira Therapeutics, Inc.: US8651104 (2014).
Google Scholar
41 Vectura Delivery Devices Limited, Boehringer Ingelheim Gmbh: US20140373839 (2014).
Google Scholar
42 Oriel Therapeutics, Inc.: US9027551 (2015).
Google Scholar
43 Hoppentocht M, Akkerman OW, Hagedoorn P, Frijlink HW, DE Boar AH. The cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family. Eur. J. Pharm. Biopharm. 90, 8–15 (2015).
Medline CASGoogle Scholar
44 Aespira Limited: US20130032145 (2013).
Google Scholar
45 Hovione International Ltd: US8677992 (2014).
Google Scholar
46 MannKind Corporation: US9192675 (2015).
Google Scholar
47 MannKind Corporation: US20160228659 (2016).
Google Scholar
48 STC UNM: US20120234322 (2012).
Google Scholar
49 King M et al. US20110253141 (2011).
Google Scholar
50 Pharmaxis Ltd.: US20140174441 (2014).
Google Scholar
51 Inhaleness BV: WO2010052323 (2010).
Google Scholar
52 Reciprocal Labs Corporation: USD757926 (2016).
Google Scholar
53 FSC Laboratories, Inc.: US20170021118 (2017).
Google Scholar
54 Matsuda H. US20160367770 (2016).
Google Scholar
55 Bell D, Mansfield L, Lomax M. Fluticasone propionate/formoterol breath-triggered inhaler: ease-of-use and patient preference. Eur. Resp. J. 48, PA4109 (2016).
Google Scholar
56 Adamis Pharmaceuticals Corporation: US20150217065 (2015).
Google Scholar
57 Young PM, Salama RO, Zhu B et al. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. Drug Dev. Ind. Pharm. 41(5), 859–865 (2015).
Medline CASGoogle Scholar
58 Pharmaxis Ltd.: US20140137865 (2014).
Google Scholar
59 Haddrell AE, Davies JF, Miles RE, Reid JP, Dailey LA, Murnane D. Dynamics of aerosol size during inhalation: hygroscopic growth of commercial nebulizer formulations. Int. J. Pharm. 463(1), 50–61 (2014).
Medline CASGoogle Scholar
60 Gaspar MM, Gobbo O, Ehrhardt C. Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulizers. J. Liposome Res. 20(1), 55–61 (2010).
Medline CASGoogle Scholar
61 Zarogoulidis P, Kioumis I, Porpodis K et al. Clinical experimentation with aerosol antibiotics: current and future methods of administration. Drug Des. Devel. Ther. 7, 1115–1134 (2013).
MedlineGoogle Scholar
62 Mexichem Amanco Holdings S.A. De C.V.: US20170027867 (2017).
Google Scholar
63 Pipeline: APC-1000 – HFA inhaled oral steroid. www.adamispharmaceuticals.com/pipeline/apc-1000/.
Google Scholar
64 Boehringer-Ingelheim Pvt Ltd: US7914770 (2011).
Google Scholar
65 Intech Biopharm Ltd: US9241904 (2016).
Google Scholar
66 Cardiff Scintigraphics Limited: US20160354564 (2016).
Google Scholar
67 Sunovion Pharmaceuticals, Inc.: US20160368858 (2016).
Google Scholar
68 Jagotec Ag: US20160310452 (2016).
Google Scholar
69 Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Int. J. Pharm. 5(5), 442–453 (2015).
Google Scholar
70 Weers J, Tarara T. The PulmoSphere platform for pulmonary drug delivery. Ther. Deliv. 5(3), 277–295 (2014).
CASGoogle Scholar
71 Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 28(42), 15015–15023 (2012).
Medline CASGoogle Scholar
72 Pearl Therapeutics, Inc.: US20170000725 (2017).
Google Scholar
73 Quinn D, Seale JP, Reisner C et al. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD. Resp. Med. 108(9), 327–335 (2014).
Google Scholar
74 Adamis Pharmaceuticals Corporation: US20150190593 (2015).
Google Scholar
75 Adamis Pharmaceuticals Corporation: US9433576 (2016).
Google Scholar
76 Rainer Schlichthaar: US20110190245 (2011).
Google Scholar
77 Adi H, Young PM, Chan HK, Aqus H, Traini D. Co-spray-dried mannitol-cisprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur. J. Pharm. Sci. 40(3), 239–247 (2010).
Medline CASGoogle Scholar
78 Alkermes Pharma: US8097282 (2012).
Google Scholar
79 Jagotec Ag: US8877251 (2014).
Google Scholar
80 Vectura Limited: WO2014106727 (2014).
Google Scholar
81 Schering Corporation: WO2010124198 (2010).
Google Scholar
82 MannKind Corporation: US8551528 (2013).
Google Scholar
83 Potocka E, Cassidy JP, Haworth P, Heuman D, van Marle S, Baughman RA Jr. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J. Diabetes Sci. Technol. 4(5), 1164–1173 (2010).
MedlineGoogle Scholar
84 MannKind Corporation: US7648960 (2010).
Google Scholar
85 Kwok PCL, Tunsirikongkon A, Glover W, Chan H-K. Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm. Res. 28, 788–796 (2011).
Medline CASGoogle Scholar
86 Insmed Incorporated: US9549939 (2017).
Google Scholar
87 Aradigm Corporation: US9545401 (2017).
Google Scholar
88 Geller DE, Weers J, Heuerding S. Development of an inhaled dry powder formulation of tobramycin using pulmosphere technology. J. Aerosol Med. Pulm. Drug Deliv. 24(4), 175–182 (2011).
Medline CASGoogle Scholar
89 Novartis Ag: US20140302147 (2014).
Google Scholar
90 Università Degli Studi “Magna Graecia” Catanzaro, Università Degli Studi Di Roma “La Sapienza”: US20120288540 (2012).
Google Scholar
91 Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J. Control. Release 185, 22–36 (2014).
Medline CASGoogle Scholar
92 Hovione International Ltd: US20160346206 (2016).
Google Scholar
93 Cooper CJ, Denyer SP, Maillard JY. Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery. Lett. Appl. Microbiol. 58, 118–122 (2014).
Medline CASGoogle Scholar
94 Golshahi L, Lynch KH, Dennis JJ, Finlay WH. In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkhloderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol. 110, 106–117 (2010).
MedlineGoogle Scholar
95 Bayer Healthcare Ag: US20120247462 (2012).
Google Scholar
96 Kolleff MH, Hamilton CW, Montgomery AB. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr. Opin. Infect. Dis. 26(6), 538–544 (2013).
MedlineGoogle Scholar
97 Kadrichu N, Boc S, Corkery K, Challoner P. In vitro efficiency of the Amikacin inhale system, a novel integrated drug-device delivery system, poster A384. Presented at: 33rd International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium, 19–22 March 2013.
Google Scholar
98 Manca ML, Cassano R, Valenti D et al. Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis. J. Pharm. Pharmacol. 65(9), 1302–1311 (2013).
Medline CASGoogle Scholar
99 Parumasivam T, Chang RY, Abdelghany S, Ye TT, Britton WJ, Chan HK. Dry powder inhalable formulations for anti-tubercular therapy. Adv. Drug Deliv. Rev. 102, 83–101 (2016).
Medline CASGoogle Scholar
100 Parumasivam T, Chan JG, Pang A et al. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment. Eur. J. Pharm. Biopharm. 107, 205–214 (2016).
Medline CASGoogle Scholar
101 Kaur K, Gupta A, Narang RK, Murthy RSR. Novel drug delivery systems: desired feats for tuberculosis. J. Adv. Pharm. Technol. Res. 1(2), 145–163 (2010).
Medline CASGoogle Scholar
102 Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob. Agents Chemother. 57(6), 2613–2619 (2013).
Medline CASGoogle Scholar
103 Wang W, Zhou QT, Sun SP et al. Effects of surface composition on the aerosolisation and dissolution of inhaled antibiotic combination powders consisting of colistin and rifampicin. AAPS J. 18(2), 372–384 (2016).
Medline CASGoogle Scholar
104 Le J, Schille DS. Aerosolized delivery of antifungal agents. Curr. Fungal Infect. Rep. 4(2), 96–102 (2010).
MedlineGoogle Scholar
105 Aradigm Corporation: US20150110855 (2015).
Google Scholar
106 Ablynx NV, Vectura Gmbh: WO2016055656 (2016).
Google Scholar
107 Pulmatrix, Inc.: US9433576 (2017).
Google Scholar
108 Topigen Pharmaceuticals, Inc.: US20120065249 (2012).
Google Scholar
109 Imaoka H, Campbell H, Babirad I et al. TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin. Exp. Allergy 41(12), 1740–1746 (2011).
Medline CASGoogle Scholar
110 Webb S. Attacks on asthma. Nat. Biotechnol. 29(10), 860–863 (2011).
Medline CASGoogle Scholar
111 Beck-Broichsitter M, Kleimann P, Gessler T, Seeger W, Kissel T, Schmehl T. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization. Int. J. Pharm. 422(1–2), 398–408 (2012).
Medline CASGoogle Scholar
112 Hsin-Yung Lin: US9339456 (2016).
Google Scholar
113 Patel AR, Chougule MB, Ian T, Patlolla R, Wang G, Singh M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm. Res. 30(5), 1435–1446 (2013).
Medline CASGoogle Scholar
114 Carvalho TC, McCook JP, Narain NR, McConville JT. Development of aqueous dispersions of coenzyme Q10 for pulmonary delivery and the dynamics of active vibrating-mesh aerosolization. Int. J. Pharm. 514(2), 407–419 (2016).
Medline CASGoogle Scholar
115 Singh D, Lohade AA, Parmar JJ et al. Development of chitosan-based dry powder inhalation system of cisplatin for lung cancer. Indian J. Pharm. Sci. 74(6), 521–526 (2012).
Medline CASGoogle Scholar
116 Cipolla D, Gonda I. Inhaled nicotine replacement therapy. Asian J. Pharm. Sci. 10(6), 472–480 (2015).
Google Scholar
117 Macleod DB, Habib AS, Ikeda K et al. Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. Anesth. Analg. 115(5), 1071–1077 (2012).
Medline CASGoogle Scholar
118 Wolff RK. Inhaled proteins and peptides in: advances in pulmonary drug delivery. Kwok PCL, Chan H-K (Eds). CRC Press, FL, USA, 1–22 (2016).
Google Scholar
119 Otitopic, Inc.: US20160022705 (2016).
Google Scholar
120 Aarhus Universitet: US20110033547 (2011).
Google Scholar
121 Merkel OM, Rubinstein I, Kissel T. SiRNA delivery to the lung: what's new? Adv. Drug. Del. Rev. 30, 112–128 (2014).
Google Scholar
122 Bains BK, Birchall JC, Toon R, Taylor G. In vitro reporter gene transfection via plasmid DNA delivered by metered dose inhaler. J. Pharm. Sci. 99(7), 3089–3099 (2010).
Medline CASGoogle Scholar
123 Jia Y, Krishnan L, Omri A. Nasal and pulmonary vaccine delivery using particulate carriers. Expert Opin. Drug Deliv. 12(6), 993–1008 (2015).
Medline CASGoogle Scholar
124 MannKind Corporation, Technovax, Inc.: US20150283069 (2015).
Google Scholar
125 Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. PNAS 109(4), 1080–1085 (2012).
Medline CASGoogle Scholar
126 MVDP author group. Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial. Vaccine 32(50), 6791–6787 (2014).
MedlineGoogle Scholar
127 Bennett JV et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull. World Health Organ. 80, 806–812 (2002).
MedlineGoogle Scholar
128 Diaz-Ortega JL, Bennett JV, Castaneda D, Vievra JR, Valdespino-Gomez JL, de Castro JF. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR. Vaccine 28, 692–698 (2010).
Medline CASGoogle Scholar
129 The United States of America as represented by The Secretary of The Department of Health and Human Services: US8481055 (2013).
Google Scholar
130 Hanif SNM, Garcia-Contreras L. Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front. Cell Infect. Microbiol. 2, 118 (2012).
MedlineGoogle Scholar
131 Hokey DA, Misra A. Aerosol vaccines for tuberculosis: a fine line between protection and pathology. Tuberculosis (Edinb.) 91(1), 2–5 (2011).
Google Scholar

Vol. 6, No. 5

Metrics

Downloaded 265 times

History

Published online 18 August 2017

Published in print September 2017

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Pulmonary drug delivery system: newer patents

Abstract

References